Asieris Pharmaceuticals Co. Ltd. has described indole phthalocyanine compounds acting as fluorescence imaging agents with high contrast reported to be useful for the diagnosis of bladder cancer.
Sunshine Lake Pharma Co Ltd. has identified pyrimidopyridine compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
B&A Oncomedical SAS has synthesized solute carrier family 12 member 2 (SLC12A2; NKCC1) inhibitors reported to be useful for the treatment of cancer, schizophrenia, autistic spectrum disorders, fragile X syndrome, Rett syndrome, Down syndrome, Parkinson’s disease and temporal lobe epilepsy, among others.
Genesis Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
Kymera Therapeutics Inc. has described salts of IL-1 receptor-associated kinase 4 (IRAK-4) degradation inducers and their crystalline forms reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.
Scientists at Centre Hospitalier Regional Universitaire de Lille, INSERM and University of Lille have divulged diphenylpyrazole compounds acting as β-amyloid (Aβ) production inhibitors and autophagy marker ratio modulators reported to be useful for the treatment of Alzheimer’s disease.
Sanwa Kagaku Kenkyusho Co. Ltd. has synthesized imidazole derivatives acting as α1A-adrenoceptor agonists reported to be useful for the treatment of orthostatic hypotension and urinary incontinence.
Appicine Therapeutics (HK) Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.